目的了解PI3K-δ过度活化综合征的临床特征及致病基因。方法回顾分析1例PI3K-δ过度活化综合征患儿的临床资料。结果患儿,男,3岁10个月,反复呼吸道感染,肝脾肿大,发育落后。提取患儿及父母外周血DNA,通过全外显子组测序及Sanger验证,证...目的了解PI3K-δ过度活化综合征的临床特征及致病基因。方法回顾分析1例PI3K-δ过度活化综合征患儿的临床资料。结果患儿,男,3岁10个月,反复呼吸道感染,肝脾肿大,发育落后。提取患儿及父母外周血DNA,通过全外显子组测序及Sanger验证,证实患儿PIK3CD基因存在错义变异c.3061G>A(E1021K),先证者父母PIK3CD基因均未发现上述变异,为新生变异。该突变使PIK3CD基因发生功能获得性突变,导致编码的p110δ活性增强,PI3K-PIP3-AKT-mTOR信号通路过度激活,诱导细胞分化增殖,致疾病发生,为致病性突变。结论 PI 3 K-δ过度活化综合征为罕见的常染色体显性遗传免疫缺陷病,基因检测可协助诊断。展开更多
AIM: To examine whether vitamin D improved viral response and predicted treatment outcome in patients with hepatitis C virus (HCV) genotype 2-3. METHODS: Fifty patients with chronic HCV genotype 2-3 were randomized co...AIM: To examine whether vitamin D improved viral response and predicted treatment outcome in patients with hepatitis C virus (HCV) genotype 2-3. METHODS: Fifty patients with chronic HCV genotype 2-3 were randomized consecutively into two groups: Treatment group [20 subjects, age 48 ± 14 years, body mass index (BMI) 30 ± 6, 65% male], who received 180 μg pegylated α-interferon-2a plus oral ribavirin 800 mg/d (Peg/RBV), together with oral vitamin D3 (Vitamidyne D drops; 2000 IU/d, 10 drops/d, normal serum level > 32 ng/mL) for 24 wk; and control group (30 subjects, age 45 ± 10 years, BMI 26 ± 3, 60% male), who received identical therapy without vitamin D. HCV RNA was assessed by reverse transcription polymerase chain reaction. Undetectable HCV RNA at 4, 12 and 24 wk after treatment was considered as rapid virological response, complete early virological response, and sustained virological response (SVR), respectively. Biomarkers of in? ammation were measured. RESULTS: The treatment group with vitamin D hadhigher BMI (30 ± 6 vs 26 ± 3, P < 0.02), and high viral load (> 400 000 IU/mL, 65% vs 40%, P < 0.01) than controls. Ninety-fi ve percent of treated patients were HCV RNA negative at week 4 and 12. At 24 wk after treatment (SVR), 19/20 (95%) treated patients and 23/30 (77%) controls were HCV RNA negative (P < 0.001). Baseline serum vitamin D levels were lower at baseline (20 ± 8 ng/mL) and increased after 12 wk vitamin D treatment, to a mean level of (34 ± 11 ng/ mL). Logistic regression analysis identifi ed vitamin D supplement [odds ratio (OR) 3.0, 95% CI 2.0-4.9, P < 0.001], serum vitamin D levels (< 15 or > 15 ng/mL, OR 2.2, P < 0.01), and BMI (< 30 or > 30, OR 2.6, P < 0.01) as independent predictors of viral response. Adverse events were mild and typical of Peg/RBV. CONCLUSION: Low vitamin D levels predicts negative treatment outcome, and adding vitamin D to conventional Peg/RBV therapy for patients with HCV genotype 2-3 signifi cantly improves viral response.展开更多
文摘目的了解PI3K-δ过度活化综合征的临床特征及致病基因。方法回顾分析1例PI3K-δ过度活化综合征患儿的临床资料。结果患儿,男,3岁10个月,反复呼吸道感染,肝脾肿大,发育落后。提取患儿及父母外周血DNA,通过全外显子组测序及Sanger验证,证实患儿PIK3CD基因存在错义变异c.3061G>A(E1021K),先证者父母PIK3CD基因均未发现上述变异,为新生变异。该突变使PIK3CD基因发生功能获得性突变,导致编码的p110δ活性增强,PI3K-PIP3-AKT-mTOR信号通路过度激活,诱导细胞分化增殖,致疾病发生,为致病性突变。结论 PI 3 K-δ过度活化综合征为罕见的常染色体显性遗传免疫缺陷病,基因检测可协助诊断。
文摘AIM: To examine whether vitamin D improved viral response and predicted treatment outcome in patients with hepatitis C virus (HCV) genotype 2-3. METHODS: Fifty patients with chronic HCV genotype 2-3 were randomized consecutively into two groups: Treatment group [20 subjects, age 48 ± 14 years, body mass index (BMI) 30 ± 6, 65% male], who received 180 μg pegylated α-interferon-2a plus oral ribavirin 800 mg/d (Peg/RBV), together with oral vitamin D3 (Vitamidyne D drops; 2000 IU/d, 10 drops/d, normal serum level > 32 ng/mL) for 24 wk; and control group (30 subjects, age 45 ± 10 years, BMI 26 ± 3, 60% male), who received identical therapy without vitamin D. HCV RNA was assessed by reverse transcription polymerase chain reaction. Undetectable HCV RNA at 4, 12 and 24 wk after treatment was considered as rapid virological response, complete early virological response, and sustained virological response (SVR), respectively. Biomarkers of in? ammation were measured. RESULTS: The treatment group with vitamin D hadhigher BMI (30 ± 6 vs 26 ± 3, P < 0.02), and high viral load (> 400 000 IU/mL, 65% vs 40%, P < 0.01) than controls. Ninety-fi ve percent of treated patients were HCV RNA negative at week 4 and 12. At 24 wk after treatment (SVR), 19/20 (95%) treated patients and 23/30 (77%) controls were HCV RNA negative (P < 0.001). Baseline serum vitamin D levels were lower at baseline (20 ± 8 ng/mL) and increased after 12 wk vitamin D treatment, to a mean level of (34 ± 11 ng/ mL). Logistic regression analysis identifi ed vitamin D supplement [odds ratio (OR) 3.0, 95% CI 2.0-4.9, P < 0.001], serum vitamin D levels (< 15 or > 15 ng/mL, OR 2.2, P < 0.01), and BMI (< 30 or > 30, OR 2.6, P < 0.01) as independent predictors of viral response. Adverse events were mild and typical of Peg/RBV. CONCLUSION: Low vitamin D levels predicts negative treatment outcome, and adding vitamin D to conventional Peg/RBV therapy for patients with HCV genotype 2-3 signifi cantly improves viral response.
